Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrative analysis of lung adenocarcinoma in EAGLE

ABSTRACT: Integrative analysis of lung adenocarcinoma in EAGLE

PROVIDER: PRJNA329162 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Integrative analysis of lung adenocarcinoma in EAGLE (phase 2)

Project description:Integrative analysis of lung adenocarcinoma in EAGLE (phase 2)

| PRJNA352760 | ENA

Integrative Analysis of Lung Adenocarcinoma

Project description:<p>We performed an integrative genomic analysis, incorporating whole exome sequence, DNA copy number, DNA methylation and transcriptome sequencing, for 101 LUAD samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study.</p>

| phs001169 | dbGaP

Lung adenocarcinoma methylation analysis.

Project description:Lung adenocarcinoma methylation analysis.

| PRJNA911747 | ENA

Homo sapiens

Project description:Integrative analysis of lung adenocarcinoma in EAGLE

| PRJNA329163 | ENA

caArray_landi-00077: EAGLE Project

Project description:The EAGLE (Environmental and Genetic Lung Cancer Etiology) gene expression study is case-control study of lung cancer conducted in Milan, Italy, designed to identify molecular alteration, particularly gene expression variation induced by smoking in lung carcinoma in this data set. The study is initiated by the Division of Cancer Epidemiology and Genetics (DCEG).

2015-11-24 | GSE75324 | GEO

Lung adenocarcinoma methylation analysis.

Project description:Methylation analysis of lung adenocarcinoma samples. Genomic DNA isolated directly from human lung adenocarcinoma specimens.

2024-08-02 | GSE220838 | GEO

Ito2019 - gefitnib resistance of lung adenocarcinoma caused by MET amplification

Project description:The model is based on publication: Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification Abstract: Gefitinib, one of the tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR), is effective for treating lung adenocarcinoma harboring EGFR mutation; but later, most cases acquire a resistance to gefitinib. One of the mechanisms conferring gefitinib resistance to lung adenocarcinoma is the amplification of the MET gene, which is observed in 5–22% of gefitinib-resistant tumors. A previous study suggested that MET amplification could cause gefitinib resistance by driving ErbB3-dependent activation of the PI3K pathway. In this study, we built a mathematical model of gefitinib resistance caused by MET amplification using lung adenocarcinoma HCC827-GR (gefitinib resistant) cells. The molecular reactions involved in gefitinib resistance consisted of dimerization and phosphorylation of three molecules, EGFR, ErbB3, and MET were described by a series of ordinary differential equations. To perform a computer simulation, we quantified each molecule on the cell surface using flow cytometry and estimated unknown parameters by dimensional analysis. Our simulation showed that the number of active ErbB3 molecules is around a hundred-fold smaller than that of active MET molecules. Limited contribution of ErbB3 in gefitinib resistance by MET amplification is also demonstrated using HCC827-GR cells in culture experiments. Our mathematical model provides a quantitative understanding of the molecular reactions underlying drug resistance.

2024-09-02 | BIOMD0000000827 | BioModels

APOLLO1: Proteogenomic analysis of lung adenocarcinoma

Project description:APOLLO1: Proteogenomic analysis of lung adenocarcinoma

| PRJNA865442 | ENA

APOLLO1: Proteogenomic analysis of lung adenocarcinoma

Project description:APOLLO1: Proteogenomic analysis of lung adenocarcinoma

| PRJNA865443 | ENA

Integrative analysis of intrinsic and adaptive resistance to KRASG12C inhibitors in lung adenocarcinoma models

Project description:Integrative analysis of intrinsic and adaptive resistance to KRASG12C inhibitors in lung adenocarcinoma models

| PRJNA689906 | ENA